In contrast, the NLV/HLA-A*0201 tetramer– fraction incorporated higher frequencies of naïve and less differentiated memory cells, with a balanced EM/E profile reminiscent of the dominant CD8+ TCR-Vβ+ expansions in dasatinib-treated CML patients and the residual CD8+ TCR-Vβ− populations in both T-LGLL and dasatinib-treated CML patients. This evidence concerns the gene HLA-A and chronic myelogenous leukemia, BCR-ABL1 positive.